GUJARAT THEMIS BIOSYN LTD.

Gujarat Themis Biosyn Limited (GTBL) has reported an indirect encumbrance on 47.02% of its equity share capital, amounting to 5,12,40,000 shares. This arises from a pledge of 51% and a non-disposal undertaking of 47.98% of the shares in Pharmaceutical Business Group (India) Limited (PBGIL) by Vividhmargi Investments Private Limited (VIPL) in favor of CTL Trusteeship Limited. PBGIL is a promoter group entity holding a significant stake in GTBL. The disclosure was made on July 3, 2026, as per SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Gujarat Themis Biosyn Limited (GTBL) has disclosed an indirect encumbrance on a significant portion of its share capital. Pharmaceutical Business Group (India) Limited (PBGIL), a promoter group entity holding 47.02% of GTBL's equity, has had its shares encumbered. This encumbrance arises from a pledge over 51% of PBGIL's shares and a non-disposal undertaking over 47.98% of PBGIL's shares, executed by Vividhmargi Investments Private Limited (VIPL) in favor of CTL Trusteeship Limited. The encumbrance is linked to a Debenture Trust Deed and a Pledge Agreement-cum-Non-Disposal Undertaking dated June 2026.

Sachin D. Patel, a promoter of Gujarat Themis Biosyn Limited, has disclosed plans to acquire up to 5,25,000 equity shares, representing approximately 0.50% of the total share capital. The acquisition is from Pharmaceutical Business Group (India) Limited and is classified as an inter-se transfer within the promoter group. The proposed acquisition price is ₹395.75 per equity share, with a total transaction value not exceeding ₹20 Crores. This transaction is exempt from making an open offer under Regulation 10(1)(a)(ii) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The acquisition is scheduled to take place between July 8, 2026, and July 14, 2026. The acquirer has declared compliance with relevant SEBI regulations.

CTL Trusteeship Limited, acting as a debenture trustee, has filed a disclosure under SEBI's Takeover Code regarding an indirect encumbrance on shares of Gujarat Themis Biosyn Limited. This arises from encumbrances placed by Vividhmargi Investments Private Limited (VIPL) on shares of Pharmaceutical Business Group (India) Limited (PBGIL), which in turn holds a significant stake in Gujarat Themis Biosyn. Specifically, VIPL has pledged 51% and placed a non-disposal undertaking on 47.988% of PBGIL's shares. The disclosure clarifies that no direct acquisition of Gujarat Themis Biosyn shares has occurred, but the encumbrances may lead to an indirect control situation.

Sachin D. Patel has acquired 24,97,190 equity shares of Gujarat Themis Biosyn Limited, representing 2.29% of the diluted share capital. The acquisition was an inter-se transfer among the promoter and promoter group, with Themis Medicare Limited being the transferor. The transaction was executed at ₹400.45 per share. This acquisition is made in reliance upon the exemption provided under Regulation 10(1)(a)(i) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as Sachin D. Patel is an immediate relative of the promoters. Prior intimation of the inter-se transfer was made on June 23, 2026, and the disclosure under Regulation 10(6) was filed on June 30, 2026.

Sachin D Patel, a promoter/promoter group member of Gujarat Themis Biosyn Limited, has filed a disclosure under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The filing details an inter-se transfer of shares among promoters. The transaction involved the acquisition/sale of 24,97,190 shares, representing 2.29% of the total share capital. Following the transaction, Sachin D. Patel's holding stands at 24,97,200 shares, also representing 2.29% of the total share capital. The total equity share capital of the company remained unchanged at Rs. 10,89,65,265/- before and after the transaction.

Gujarat Themis Biosyn Ltd (GTBL) has initiated an arbitration proceeding against Optimus Drugs Private Limited (Optimus Drugs) for allegedly terminating a supply agreement contrary to agreed terms. GTBL is claiming ₹75,00,00,000 for Break Fees due to breach of 'Take-or-Pay' obligations, ₹23,80,849 towards interest on delayed payments, and ₹15,00,00,000 for damages and financial losses, totaling approximately ₹98.8 crore. The company does not anticipate any negative financial implications from penalties as it is seeking recovery and damages.

Gujarat Themis Biosyn Ltd has announced the closure of its trading window effective July 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will remain shut until 48 hours after the declaration of the un-audited financial results for the quarter ending June 30, 2026. The specific date for the Board Meeting to consider these financial results will be communicated later. This measure is standard practice to prevent insider trading during sensitive financial reporting periods.

Sachin D. Patel, a promoter of Gujarat Themis Biosyn Limited, intends to acquire up to 2.38% of the company's equity shares from Themis Medicare Limited. The transaction, valued at approximately ₹100 crore, involves an inter-se transfer within the promoter group. The acquisition is scheduled between June 30, 2026, and July 3, 2026. This move is exempt from an open offer under Regulation 10(1)(a)(ii) of SEBI (SAST) Regulations, 2011, as the acquisition price is within the permissible limits of the volume-weighted average market price.

Gujarat Themis Biosyn Ltd has announced the cancellation of its Board Meeting, which was originally scheduled for Friday, June 19, 2026. The company stated that the meeting was called off due to "unavoidable circumstances." This cancellation follows an earlier intimation dated June 16, 2026, regarding the meeting. Gujarat Themis Biosyn Ltd has committed to informing the Stock Exchanges about the revised date for the Board Meeting in due course, ensuring compliance with the applicable timelines prescribed under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.